Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.
Details of the company’s participation are as follows:
Citi’s 18th Annual BioPharma Conference
Date: Thursday, September 7th
H.C. Wainwright 25th Annual Global Investment Conference
Date and Time: Monday, September 11th at 4:00 P.M. ET
TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Date and Time: Wednesday, September 20th at 11:00 A.M. ET
Location: Virtual (no webcast)
The webcast for the fireside chat will be available on atai’s website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. A replay will be available following the live event.
About Atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.
Atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.